Hepatitis B immunoglobulin (HBIG) has been routinely applied in the liver transplantation setting to block HBV reinfection of grafts. However, new monoclonal anti-HBV surface antibodies have been developed to replace HBIG. The epitopes of such monoclonal antibodies may affect the emergence of escape variants and deserve study.

中文翻译：

---

通过体内选择 HBV 逃逸变体绘制针对 HBsAg 的治疗性单克隆抗体的构象表位

乙型肝炎免疫球蛋白 (HBIG) 已常规应用于肝移植环境中，以阻止移植物的 HBV 再感染。然而，已经开发出新的单克隆抗HBV表面抗体来替代HBIG。这种单克隆抗体的表位可能会影响逃逸变体的出现，值得研究。